The Food and Drug Administration (FDA) announced the Rare Disease Framework Initiative to develop a more consistent, flexible and tailored approach to reviewing drugs and biologics for rare diseases. The initiative seeks to align regulatory expectations with the realities of rare disease development, including small patient populations, limited understanding of disease progression and challenges generating traditional clinical trial evidence. According… (Colocho, October 14, 2026) #Food and Drug Administration, #Prescription Drugs